Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Eisai Co. Ltd (OP:ESALF)

28.55 -1.45 (-4.84%)
Streaming Delayed Price Updated: 1:23 PM EST, Dec 17, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Eisai Co. Ltd

< Previous 1 2 3 Next >
News headline image
Merck/Eisai's Keytruda Plus Lenvima Regime Shows Mixed Data In Esophagus Cancer Study ↗
Merck and Eisai report mixed results from LEAP-015 trial of Keytruda and Lenvima in HER2-negative gastroesophageal cancer treatment. 
Via Benzinga
News headline image
Biogen's Alzheimer's Drug Secures UK Approval, But An Independent Agency Does Not Recommend Reimbursement ↗
The U.K.'s Medicines and Healthcare products Regulatory Agency approved Eisai and Biogen's Leqembi for treating mild cognitive impairment and mild dementia due to Alzheimer's. Despite this, NICE stated... 
Via Benzinga
News headline image
Biogen/Eisai's Alzheimer's Drug Leqembi Gets 'No Go' From European Drug Regulator's Advisory Panel, Cites Serious Side Events ↗
The European Medicines Agency's CHMP has rejected the approval of Eisai and Biogen's Alzheimer's treatment lecanemab, citing concerns over its risks. Eisai plans to appeal the decision and work towards... 
Via Benzinga
News headline image
Bernie Sanders: 'Getting Sick In America Should Not Mean Going Bankrupt, Losing Your Home, Car, Or Life Savings' ↗
 
Via Benzinga
Topics Bankruptcy
News headline image
Current Analysis: Eisai Co Ltd (ESAIY) ↗
Eisai Co Ltd’s most recent $0.14 semi-annual dividend, paid June 12th to shareholders of record March 30th, equates to $0.28 annually and throws a yield of 1.74% as of Friday’s closing price. 
Via Talk Markets
News headline image
Eli Lilly's Alzheimer's Therapy's Broad Label Reflects Regulatory Confidence in Anti-Amyloid Antibodies: Analyst ↗
The FDA has approved Eli Lilly's Kisunla (donanemab) for early symptomatic Alzheimer's disease. Kisunla, targeting amyloid plaques, shows a significant reduction in disease progression and may reduce... 
Via Benzinga
News headline image
Why Is Eli Lilly Stock Trading Higher Premarket Tuesday? ↗
Shares of Eli Lilly surged as an FDA advisory committee endorsed donanemab, an Alzheimer's treatment shown to significantly impact early-stage patients. The drug's benefits outstripped risks, setting... 
Via Benzinga
News headline image
European Medicines Agency Delays Approval Decision For Biogen-Eisai Partnered Alzheimer's Drug Lecanemab ↗
Biogen and Eisai face delays as EMA postpones the oral explanation for the lecanemab review. Procedural issues at EMA prompt setback, impacting drug evaluation process amid recent EU court ruling. 
Via Benzinga
News headline image
Merck, Eisai Report Yet Another Failure For Keytruda Plus Lenvima Combo Trial, This Time In Endometrial Cancer ↗
Merck & Co Inc (NYSE: MRK) and Eisai Co Ltd (OTC: ESALY) (OTC: ESALF) announced that the Phase 3 LEAP-001 trial of Keytruda (pembrolizu 
Via Benzinga
News headline image
Improved Alzheimer's Diagnosis Access: CMS Expands Amyloid PET Scan Usage ↗
The U.S. 
Via Benzinga
News headline image
LuMind CEO At Odds With Neurologists Over Alzheimer's Drugs Made By Biogen, Eli Lilly ↗
Hampus Hillerstrom, CEO of the Down syndrome research organization LuMind IDSC, is advocating for access to Alzheimer's drugs made by Eisai Co Ltd (OTC: ESALY)/ Biogen Inc's (NASDAQ: 
Via Benzinga
News headline image
Amazon Invests $4B In ChatGPT Competitor, Hollywood Writers Accept Tentative Deal, ChatGPT Challenges Siri And Alexa With Introduction Of Verbal Responses: Today's Top Stories ↗
Benzinga 
Via Benzinga
News headline image
Japan's Regulatory Authority Approves Biogen/Eisai's Alzheimer Treatment Leqembi ↗
Eisai Co Ltd (OTC: ESALY) (OTC: ESALF) and Biogen Inc (NASDAQ: BIIB) announced that humanized anti-soluble aggregated amyloid-beta (A&be 
Via Benzinga
News headline image
Merck-Eisai Partnered Two Keytruda/Lenvima Combo Trials Flunk In Certain Types Of Lung Cancer ↗
Merck & Co Inc (NYSE: MRK) and Eisai Co Ltd (OTC: ESALY) (OTC:  
Via Benzinga
News headline image
Merck/Eisai's Cancer Combo Therapy Ambition Dashed Once Again, Companies Throw Towel On Head & Neck Trial ↗
Merck & Co Inc (NYSE: MRK) and Eisai Ltd (OTC: ESALY) provided an update on the Phase 3 LEAP-010 trial evaluating Keytruda (pembrolizumab), plus Lenvima for recurrent or metastatic head and neck... 
Via Benzinga
News headline image
Expanded Medicare Coverage For Biogen-Eisai's Leqembi Signals a Turning Point in Alzheimer's Treatment: Analysts ↗
The FDA approved a supplemental marketing application for Biogen Inc (NASDAQ: BIIB)-Eisai Co Ltd (OTC: ESALY) supporting the traditional approval of Leqembi (lecanemab-irmb), making it the first and... 
Via Benzinga
News headline image
Alzheimer's Drug Leqembi Faces Hurdles in Europe: Concerns Over Health Risks and Healthcare Resources ↗
Experts in Europe considering the potential use of a new Alzheimer's disease drug developed by Eisai Co Ltd (OTC: ESALY) and Biogen Inc (NASDAQ: BIIB) say Leqembi (lecanemab)'s ability to slow 
Via Benzinga
News headline image
Prospects for Full Approval of Eisai and Biogen's Leqembi Shine Brighter after FDA Committee Vote ↗
Friday, the FDA's Peripheral and Central Nervous System Drugs Advisory Committee voted unanimously that the data from Eisai Co Ltd (OTC: ESALY) and Biogen Inc (NASDAQ: BIIB) Phase 3 Clarity AD tria 
Via Benzinga
News headline image
Bernie Sanders Takes on High Costs of Alzheimer's Treatment Leqembi, Calls Price Tag 'Unconscionable' ↗
Senator Bernie Sanders urged the U.S. 
Via Benzinga
News headline image
FDA Signals Support for Eisai-Biogen Alzheimer's Drug Data Confirms Benefits For Complete Approval ↗
FDA Peripheral and Central Drugs Advisory Committee is meeting Friday (June 9) to discuss a supplemental marketing application for Leqembi (lecanemab) submitted by Eisai Co Ltd (OTC: ESALY) for... 
Via Benzinga
News headline image
Analysts Say Eli Lilly's Donanemab In Alzheimer's Is Encouraging, Outline Potential Implications For Biogen ↗
Wednesday, Eli Lilly And Co (NYSE: LLY) announced positive results of the TRAILBLAZER-ALZ 2 Phase 3 study of  
Via Benzinga
News headline image
Will US Medicare Fully Cover Alzheimer's Drugs? Eli Lilly Thinks Yes! ↗
Eli Lilly And Co (NYSE: LLY) expects the U.S. Medicare health plan to loosen its grip on the coverage limits on new Alzheimer's drugs, as more data emerging in coming weeks show that clearing amyloid... 
Via Benzinga
News headline image
Merck, Eisai Shelve Keytruda Plus Lenvima Combo Trial In Skin Cancer Setting, Disappoints In Certain Type Of Colorectal Cancer ↗
 
Via Benzinga
News headline image
National Institute on Aging Aims Building $300M Alzheimer's Research Database ↗
The U.S. National Institute on Aging (NIA), part of the government's National Institutes of Health (NIH), aims to build an Alzheimer's research database. Alzheimer's Association Chief Science Officer... 
Via Benzinga
News headline image
Eisai-Biogen Highlights Additional Data From Recently Approved Alzheimer's Drug ↗
 
Via Benzinga
News headline image
Alzheimer's Association Launches Grassroots Level Lobbying For Medicare Coverage Of Alzheimer's Treatments ↗
 
Via Benzinga
News headline image
Analyst Says Biogen-Eisai's Alzheimer's Treatment Leqembi Coverage Enables Access To Over $2.5B Market Opportunity ↗
 
Via Benzinga
News headline image
Eisai-Biogen Seek Complete FDA Approval For Its Second Alzheimer's Treatment ↗
 
Via Benzinga
News headline image
The 7 Best Growth Stocks to Buy for February 2023 ↗
Some of the best growth stocks are lesser-known names that have the ability to provide tremendous long-term upside for investors. 
Via InvestorPlace
News headline image
FDA Approves Biogen's Second Alzheimer's Treatment Under Accelerated Pathway ↗
 
Via Benzinga
< Previous 1 2 3 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.